Neuraxis, INC financial data

Symbol
NRXS on NYSE
Industry
Electromedical & Electrotherapeutic Apparatus
Location
11611 N. Meridian St, Suite 330, Carmel, IN
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 21.3 %
Quick Ratio 0.67 %
Debt-to-equity -145 %
Return On Equity 288 % +34.5%
Return On Assets -641 %
Operating Margin -298 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.98M shares +40.1%
Common Stock, Shares, Outstanding 6.98M shares +35.6%
Common Stock, Value, Issued 6.98K USD +35.6%
Weighted Average Number of Shares Outstanding, Basic 7.17M shares +97.8%
Weighted Average Number of Shares Outstanding, Diluted 7.17M shares +97.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 477K USD -22.8%
Revenue from Contract with Customer, Excluding Assessed Tax 2.46M USD +39.6%
Research and Development Expense 130K USD +61.1%
General and Administrative Expense 9.02M USD -38.2%
Operating Income (Loss) -7.32M USD +45.4%
Net Income (Loss) Attributable to Parent -8.39M USD +35.7%
Earnings Per Share, Basic -0.72 USD/shares +89.5%
Earnings Per Share, Diluted -0.72 USD/shares +89.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 261K USD -65.7%
Accounts Receivable, after Allowance for Credit Loss, Current 52.6K USD -60.3%
Inventory, Net 22.5K USD -35%
Assets, Current 632K USD -34.7%
Property, Plant and Equipment, Net 94.2K USD +17.3%
Operating Lease, Right-of-Use Asset 298K USD +282%
Assets 1.14M USD -7.5%
Accounts Payable, Current 962K USD +69.8%
Accrued Liabilities, Current 1.17M USD +318%
Liabilities, Current 2.66M USD +18%
Operating Lease, Liability, Noncurrent 273K USD +594%
Liabilities 2.94M USD +27.9%
Retained Earnings (Accumulated Deficit) -55.4M USD -17.9%
Stockholders' Equity Attributable to Parent -1.79M USD -69.1%
Liabilities and Equity 1.14M USD -7.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.33M USD -114%
Net Cash Provided by (Used in) Financing Activities 1.35M USD +220%
Net Cash Provided by (Used in) Investing Activities -14.7K USD -93.5%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 6.98M shares +35.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.19K USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 16.9K USD -52.9%
Deferred Tax Assets, Valuation Allowance 10.9M USD +41.9%
Operating Lease, Liability 329K USD +290%
Depreciation 7.61K USD -3.29%
Payments to Acquire Property, Plant, and Equipment 14.7K USD +93.5%
Lessee, Operating Lease, Liability, to be Paid 449K USD +421%
Property, Plant and Equipment, Gross 464K USD +10.4%
Operating Lease, Liability, Current 56.4K USD +24.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 108K USD +384%
Lessee, Operating Lease, Liability, to be Paid, Year One 105K USD +288%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 120K USD +7223%
Lessee, Operating Lease, Liability, to be Paid, Year Three 86.9K USD +224%
Deferred Tax Assets, Operating Loss Carryforwards 6.57M USD +98.6%
Preferred Stock, Shares Authorized 5M shares +346%
Lessee, Operating Lease, Liability, to be Paid, Year Four 89K USD
Additional Paid in Capital 53.5M USD +16.7%
Amortization of Intangible Assets 2.62K USD +440%
Depreciation, Depletion and Amortization 10.7K USD +9.02%
Interest Expense 189K USD -37%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%